

## **Assessing the COVID-19 Pandemic's Impact on Breast Cancer Appointment Scheduling**

Alan Van Tiggelen

Muhammad A. Rizvi MD

Follow this and additional works at: <https://scholarlyworks.lvhn.org/research-scholars>



Part of the [Medicine and Health Sciences Commons](#)

---

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact [LibraryServices@lvhn.org](mailto:LibraryServices@lvhn.org).

# Assessing the COVID-19 Pandemic's Impact on Breast Cancer Appointment Scheduling

Alan Van Tiggelen, Muhammad A. Rizvi, MD  
Lehigh Valley Health Network, Allentown, Pennsylvania

## Background

- Female breast cancer was the most common newly diagnosed cancer in women in 2019 and had the second lowest survival rate in the United States<sup>1</sup>
- Regular screening mammography has been associated with a decrease in breast cancer mortality rates<sup>2</sup>
- Patient surveys taken during the early stages of the COVID-19 pandemic revealed significant disruptions in cancer treatment which potentially increased the risk of poor outcomes<sup>3</sup>
- Delays in screening mammography due to the COVID-19 pandemic have been shown to increase the proportion of patients diagnosed with more advanced stages of breast cancer<sup>4</sup>

## Methods

A retrospective review was conducted using medical history and appointment data collected from patient charts that conformed to the study criteria. Two groups were established: patients diagnosed pre-pandemic (3/1/19 - 12/31/19, n = 46) and patients diagnosed during the pandemic (3/1/20 - 12/31/20, n = 58).

### Inclusion Criteria

- Female patients aged 18+
- Newly diagnosed breast cancer
- Diagnosed between March 1, 2019 to December 31, 2019 OR from March 1, 2020 to December 31 2020

### Exclusion Criteria

- Prior personal and/or family history of cancer
- Diagnosis made outside of the Lehigh Valley Health Network
- Pregnancy during the timeframe of the study

## Results

Table 1. Appointment cancellation rates of breast cancer patients diagnosed pre-pandemic and during the pandemic

Appointment Type	Pre-pandemic Group Size	Pandemic Group Size	Pre-pandemic Cancellation Rate	Pandemic Cancellation Rate
Screening Mammogram	27	22	14.81%	27.27%
Diagnostic Mammogram	37	51	13.51%	15.69%
First Recommended Treatment	46	58	4.35%	10.34%
Overall	110	130	10%	15.38%

Table 2. Stage distribution of breast cancer at time of diagnosis

Group	Stage 0	Stage 1	Stage 2	Stage 3	Stage 4
Pre-pandemic	15.91%	63.64%	9.09%	2.27%	9.09%
Pandemic	10.52%	56.14%	12.28%	5.26%	15.79%




Figure 1: Visual comparison of stage distribution between patient groups

## Conclusions

- Screening and diagnostic mammography, as well as initial treatment appointments for newly diagnosed breast cancer patients were cancelled at a higher rate during the pandemic
- Patients diagnosed during the pandemic were more likely to have a higher (2+) stage cancer than patients diagnosed prior to the pandemic
- The disruptions in screening mammography due to the COVID-19 pandemic within the Lehigh Valley Health Network likely contributed to the increase in advanced stages of cancer at diagnosis
- Preparations to preserve screening appointments from being disrupted in the future would be beneficial in mitigating the risk of negative patient outcomes

## Limitations and Future Research

- Due to the small number of patients (n = 104) used in this study the data is not representative of all newly diagnosed breast cancer patients in the studied time intervals
- Excluding patients with a family history of all cancers significantly decreased the number of eligible patients to include in the study
- Further study using an expanded data set is ongoing and may provide statistics that better represent the general breast cancer patient population within the network

### References

- U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2021 submission data (1999-2019): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; [www.cdc.gov/cancer/dataviz](http://www.cdc.gov/cancer/dataviz), released in June 2022.
- Linda L. Humphrey, Mark Helfand, Benjamin K.S. Chan, et al; Breast Cancer Screening: A Summary of the Evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2002;137:347-360. [Epub 3 September 2002]. doi:10.7326/0003-4819-137-5\_Part\_1-200209030-00012
- Papautsky, E.L., Hamlish, T. Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic. *Breast Cancer Res Treat* 184, 249–254 (2020). <https://doi.org/10.1007/s10549-020-05828-7>
- Figueroa, J. D., Gray, E., Pashayan, N., Deandrea, S., Karch, A., Vale, D. B., Elder, K., Procopio, P., Ravesteyn, N. T. van, Mutabi, M., Canfell, K., & Nickson, C. (2021, June 30). *The impact of the COVID-19 pandemic on breast cancer early detection and screening*. Preventive Medicine. Retrieved July 24, 2022, from <https://doi.org/10.1016/j.ypmed.2021.106585>

**Acknowledgements:** We thank Melissa Kratz RN, MSN, AOCNS, for assisting in the data collection and review process.